CD163 and neoplasm: Interestingly, in phase II clinical trial on ESCC patients, a low dose of metformin does not increase the total number of F4/80+ macrophage populations; however, it decreases tumor-promoting CD163+ macrophages and increases tumor-suppressive CD11c+ macrophages [28].